Integration of Ruxolitinib into Dose-Intensified Therapy Targeted Against a Novel JAK2 F694L Mutation in B-precursor Acute Lymphoblastic Leukemia

A 17-year-old female with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with persistent minimal residual disease (MRD) with standard chemotherapy was found to have a BCR-ABL1-like gene expression pattern. Genome sequencing revealed a JAK2 mutation not previously described in BCP-ALL and a...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Pediatr Blood Cancer
Main Authors: Mayfield, Jodi R., Czuchlewski, David R., Gale, James M., Matlawska-Wasowska, Ksenia, Vasef, Mohammad A., Nickl, Christian, Pickett, Gavin, Ness, Scott A., Winter, Stuart S.
Formato: Artigo
Idioma:Inglês
Publicado: 2016
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5366086/
https://ncbi.nlm.nih.gov/pubmed/27860260
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.26328
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares